Guideline Recommendations for Managing Penile Shrinkage in Men Receiving Androgen Deprivation Therapy
Pre‑Treatment Counseling
- The American Cancer Society and the National Comprehensive Cancer Network recommend that clinicians explicitly counsel men scheduled to start ADT about the risk of body‑image changes, including penile shortening, and arrange referral to supportive counseling when patients express distress. [1][2]
Routine Follow‑Up Practices
- Clinicians should proactively inquire about sexual function and body‑image concerns at each follow‑up visit because many men do not volunteer this information spontaneously. [1][2]
Baseline Sexual Function Assessment
- Prior to initiating ADT, baseline sexual function should be documented using validated instruments such as the Sexual Health Inventory for Men (IIEF‑5) or the Expanded Prostate Cancer Index Composite (EPIC‑CP). [3][4]
Management of Co‑Occurring Erectile Dysfunction
- First‑line therapy for erectile dysfunction that frequently accompanies penile shortening during ADT is treatment with phosphodiesterase‑5 inhibitors, with aggressive management recommended. [2][5]
Distinguishing Penile Shortening from Erectile Dysfunction
- Guidelines emphasize that penile shortening and erectile dysfunction are separate entities; both should be addressed individually in counseling and treatment planning. 2